Magali Zeisser Labouebe

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Mass Spectrometry

Binding Protein

Capillary Electrophoresis

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Solene Masloh, Anne Chevrel, Maxime Culot, Anaëlle Perrocheau, Yogeshvar N Kalia, Samuel Frehel, Rémi Gaussin, Fabien Gosselet, Simon Huet, Magali Zeisser Labouebe, Leonardo Scapozza
Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model. Pharmaceutics 16 (1) (2024)
Solene Masloh, Anne Chevrel, Maxime Culot, Anaëlle Perrocheau, Yogeshvar N Kalia, Samuel Frehel, Rémi Gaussin, Fabien Gosselet, Simon Huet, Magali Zeisser Labouebe, Leonardo Scapozza
Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model. Pharmaceutics 16 (1) (2024)
Solene Masloh, Anne Chevrel, Maxime Culot, Anaëlle Perrocheau, Yogeshvar N Kalia, Samuel Frehel, Rémi Gaussin, Fabien Gosselet, Simon Huet, Magali Zeisser Labouebe, Leonardo Scapozza
Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model. Pharmaceutics 16 (1) (2024)
Solene Masloh, Maxime Culot, Fabien Gosselet, Anne Chevrel, Leonardo Scapozza, Magali Zeisser Labouebe
Challenges and Opportunities in the Oral Delivery of Recombinant Biologics. Pharmaceutics 15 (5) (2023)
Simon Huet, Magali Zeisser Labouebe, Rute Castro, Perrine Jacquot, Jessy Pedrault, Sébastien Viollet, Gaetan Van Simaeys, Gilles Doumont, Lionel Larbanoix, Egor Zindy, António E Cunha, Leonardo Scapozza, Mathieu Cinier
Targeted Nanofitin-drug conjugates achieve efficient tumor delivery and therapeutic effect in an EGFR-positive mouse xenograft model. Molecular cancer therapeutics (2023)